Asegua Therapeutics LLC
UnclaimedPharmaceutical Preparation ManufacturingFoster City, CA
Founded
2018
Primary NAICS
325412
CAGE code
88RM7
Federal awards
—
Overview
Asegua Therapeutics is providing access to hepatitis C therapies with two new drugs: authorized generic of HARVONI® (ledipasvir/sofosbuvir) and authorized generic of EPCLUSA® (sofosbuvir/velpatasvir).
Classification
This U.S. industry comprises establishments primarily engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations (except biological) intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.
- Manufacturing32
- Chemical Manufacturing325
- Pharmaceutical and Medicine Manufacturing32541
- Pharmaceutical Preparation Manufacturing325412
Federal awards
| Year | Agency | Obligated | Actions |
|---|---|---|---|
| 2026 | Department of Veterans Affairs | $0 | 3 |
| 2025 | Department of Veterans Affairs | $0 | 8 |
| 2024 | Department of Veterans Affairs | $0 | 3 |
| 2023 | Department of Veterans Affairs | $0 | 9 |
| 2022 | Department of Veterans Affairs | $0 | 3 |